Underlying Mechanisms and Signs of CRS
The panel discusses the mechanisms believed to cause cytokine release syndrome associated with CAR T-cell therapy and the signs and symptoms.
EP: 1.Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy
EP: 2.Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach
EP: 3.Patient Profile 1: Managing CRS Following CAR T-Cell Therapy
Now Viewing
EP: 4.Underlying Mechanisms and Signs of CRS
EP: 5.Strategies to Manage or Mitigate CRS
EP: 6.Patient Profile 2: Managing ICANS Following CAR T-Cell Therapy
EP: 7.Clinical Practices for Treating ICANS Following CAR T-Cell Therapy
EP: 8.The Importance of Multidisciplinary Collaboration in CRS Management
EP: 9.Supportive Care Strategies for CAR T-Cell Therapy Recipients
EP: 10.Managing Cytopenias and HLH/MAS Following CAR T-Cell Therapy
EP: 11.Unmet Needs and Future Perspectives for CAR T-Cell Therapy in R/R MM
Video content above is prompted by the following question:
- What are the proposed mechanisms believed to cause cytokine release syndrome (CRS) associated with CAR T-cell therapy?
Recent Videos
Related Content
!["[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2Fb319d51b3dcc8ae143eae44a72a0aff757b330db-800x533.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"[O]ur analysis supports the clinical efficacy and safety of IsaKd as a first-salvage therapy in a specific, and still existing, subset of [patients with multiple myeloma] who relapse during lenalidomide maintenance following autologous stem cell transplantation,\" according to the study authors.")
![“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F4de1e119837b011168a7884a19a600b14bb6a258-3600x2400.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "“These findings highlight the critical need to address PEM in the management of [patients with multiple myeloma] with ACHF to mitigate the associated poor clinical outcomes,” according to the study authors.")
